Welcome

11 November 2013: 5-year results of the TARGIT-A trial were published in the The Lancet  

Results:

• When TARGIT is given with lumpectomy, the 5-year local recurrence of breast cancer is similar to EBRT
• When TARGIT is given as a second procedure, the difference in local recurrence between TARGIT and EBRT was more than 2.5%
• Breast cancer mortality with TARGIT were similar to EBRT
• Mortality from other causes  was significantly lower with TARGIT due to fewer deaths from  cardiovascular causes and other cancers.
• The results remain stable with longer follow up.

Click here to access

•  The 5-year reults of TARGIT IORT for breast cancer- the full paper at the Lancet 

• PDF download TARGIT-IORT-for-breast-cancer-Lancet-2013

•  The Lancet podcast describing the results

  6 Dec 2012: TARGIT-A trial updated results presented at San Antonio Breast Cancer Symposium (General Session 4) Link which does not need Flash: IORT for Breast Cancer

  5 June 2010: TARGIT-A trial results published in the Lancet Online First

  TARGIT is an acronym for (TARGeted Intraoperative radioTherapy). TARGIT is a procedure of giving radiotherapy (radiation treatment) to the tissues surrounding a breast cancer  (tumour bed) in the operating theatre (operating room) after its surgical removal. The rationale of TARGIT is to accurately target the tissues where there is the highest risk of cancer returning. The technique was designed in 1998 at the University College London by Jayant S Vaidya and  Michael Baum along with Jeffrey Tobias. One can say that TARGIT is a special method of intraoperative radiation therapy (IORT) The TARGIT-A trial is a randomized controlled clinical trial to test whether radiation treatment given by the single-dose TARGIT procedure is equivalent to conventional course of external beam postoperative radiotherapy for breast cancer which is normally given to the whole breast over a course of several weeks. Targeting radiotherapy to the tumor bed after breast cancer is surgically removed means it can be delivered accurately, at the time of surgery, does not delay adjuvant chemotherapy, and could allow breast conserving surgery (rather than mastectomy) when the 5 or 6-week course of postoperative radiotherapy is not desirable or practical.  History, scientific publications, presentations, operative videos are available at the TARGIT-A Trial and results website Click below for more information about Targeted Intra-operative Radiotherapy (TARGIT) for breast cancer. Breast Cancer Treatment: Healthcare Providers
  Breast Cancer Treatment: Patient Corner